Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Reqorsa (quaratusugene ozeplasmid)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Genprex

Drug class:

Apoptosis stimulant, Immunomodulator, Gene transference, TUSC2 gene stimulant

Related drugs:

aglatimagene besadenovec (6)

retroviral expression vectors bearing inhibitory genes (0)

E7 TCR cells (0)

LPX EWS/FL1 T1 (0)

rAAV2tYF-PR1.7-hCNGB3 (0)

lurbinectedin (11)

arsenic trioxide (6)

omacetaxine mepesuccinate (4)

teserpaturev (1)

ABI-1968 topical cream (0)

autologous γδ T lymphocytes (0)

84AA-API 14AA (0)

alpha-tocopheroloxyacetic acid (0)

darinaparsin (0)

elemene injection (0)

BS-HH-002.SA (0)

piceatannol (0)

hydroxychloroquine (7)

SQZ-AAC-HPV (1)

HLA-matched donor mononuclear enriched leukocytes (0)

rimiducid activated rivogenlecleucel (0)

coprelotamab (0)

GSK2302024A (0)

MVA-BN-HER2 (0)

nelipepimut-S (0)

engineered donor allograft cell therapy (0)

parvovirus H-1 (0)

FT1050+FT4145 programmed mPB (0)

allodepleted T-cell immunotherapeutics (0)

TAEK-VAC-HerBy vaccine (0)

Undisclosed CISH inactivated TIL (0)

thymalfasin (0)

chlorogenic acid (0)

dendritic cell activation therapy (0)

minocycline (0)

aglatimagene besadenovec (6)

retroviral expression vectors bearing inhibitory genes (0)

E7 TCR cells (0)

LPX EWS/FL1 T1 (0)

rAAV2tYF-PR1.7-hCNGB3 (0)

›

No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	pembrolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials pembrolizumab + quaratusugene ozeplasmid Sensitive : B	pembrolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials pembrolizumab + quaratusugene ozeplasmid Sensitive : B
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	atezolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials atezolizumab + quaratusugene ozeplasmid Sensitive : B	atezolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials atezolizumab + quaratusugene ozeplasmid Sensitive : B
KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	pembrolizumab + quaratusugene ozeplasmid Sensitive: D – Preclinical pembrolizumab + quaratusugene ozeplasmid Sensitive : D	pembrolizumab + quaratusugene ozeplasmid Sensitive: D – Preclinical pembrolizumab + quaratusugene ozeplasmid Sensitive : D